GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » Beneish M-Score

GemPharmatech Co (SHSE:688046) Beneish M-Score : -2.21 (As of May. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is GemPharmatech Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.21 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for GemPharmatech Co's Beneish M-Score or its related term are showing as below:

SHSE:688046' s Beneish M-Score Range Over the Past 10 Years
Min: -2.34   Med: -2.2   Max: -1.3
Current: -2.21

During the past 6 years, the highest Beneish M-Score of GemPharmatech Co was -1.30. The lowest was -2.34. And the median was -2.20.


GemPharmatech Co Beneish M-Score Historical Data

The historical data trend for GemPharmatech Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemPharmatech Co Beneish M-Score Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - -1.71 -2.34

GemPharmatech Co Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -2.31 -2.20 -2.34 -2.21

Competitive Comparison of GemPharmatech Co's Beneish M-Score

For the Biotechnology subindustry, GemPharmatech Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GemPharmatech Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GemPharmatech Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where GemPharmatech Co's Beneish M-Score falls into.



GemPharmatech Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of GemPharmatech Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2089+0.528 * 1.0428+0.404 * 0.6451+0.892 * 1.1817+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9728+4.679 * 0.030953-0.327 * 1.3305
=-2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥324.6 Mil.
Revenue was 157.087 + 167.623 + 158.7 + 155.56 = ¥639.0 Mil.
Gross Profit was 103.666 + 106.397 + 111.643 + 105.395 = ¥427.1 Mil.
Total Current Assets was ¥1,648.1 Mil.
Total Assets was ¥2,559.4 Mil.
Property, Plant and Equipment(Net PPE) was ¥636.7 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥152.7 Mil.
Total Current Liabilities was ¥340.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥38.3 Mil.
Net Income was 29.479 + 41.2 + 40.146 + 46.518 = ¥157.3 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0.0 Mil.
Cash Flow from Operations was -52.605 + 79.419 + 10.939 + 40.367 = ¥78.1 Mil.
Total Receivables was ¥227.3 Mil.
Revenue was 140.305 + 130.266 + 135.914 + 134.243 = ¥540.7 Mil.
Gross Profit was 97.233 + 85.707 + 94.449 + 99.503 = ¥376.9 Mil.
Total Current Assets was ¥1,510.2 Mil.
Total Assets was ¥2,323.9 Mil.
Property, Plant and Equipment(Net PPE) was ¥427.2 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0.0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥132.9 Mil.
Total Current Liabilities was ¥221.2 Mil.
Long-Term Debt & Capital Lease Obligation was ¥37.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(324.635 / 638.97) / (227.25 / 540.728)
=0.50806 / 0.420267
=1.2089

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(376.892 / 540.728) / (427.101 / 638.97)
=0.697008 / 0.668421
=1.0428

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1648.108 + 636.728) / 2559.431) / (1 - (1510.222 + 427.195) / 2323.892)
=0.107288 / 0.166305
=0.6451

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=638.97 / 540.728
=1.1817

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 427.195)) / (0 / (0 + 636.728))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(152.722 / 638.97) / (132.857 / 540.728)
=0.239013 / 0.2457
=0.9728

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((38.341 + 340.773) / 2559.431) / ((37.482 + 221.243) / 2323.892)
=0.148124 / 0.111333
=1.3305

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(157.343 - 0 - 78.12) / 2559.431
=0.030953

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

GemPharmatech Co has a M-score of -2.21 suggests that the company is unlikely to be a manipulator.


GemPharmatech Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of GemPharmatech Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


GemPharmatech Co (SHSE:688046) Business Description

Traded in Other Exchanges
N/A
Address
No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of?genetically engineered mouse?models?and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of?cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech Co (SHSE:688046) Headlines

No Headlines